People
As Moderna launched its Phase III clinical trial of its COVID-19 vaccine this week, a member of the company’s board of directors, Elizabeth “Betsy” Nabel, resigned to avoid any conflict of interest.
A multi-omics, multi-algorithm approach will unleash a new wave of understanding around Alzheimer’s disease and diagnosis, that in time, will make precision diagnostics practical, speakers predicted at the Alzheimer’s Association International Conference 2020.
Biopharma and life science companies strengthen their leadership teams and board with these Movers & Shakers.
As the world continues to navigate through the coronavirus pandemic, many biopharma companies are surging ahead with job creations. Check out these companies that have made recent job expansion announcements.
The vaccine was developed by Preston Estep, a former graduate student of Harvard University geneticist George Church.
Genentech is eliminating 474 employees, mostly based out of its South San Francisco facilities. The job cuts are expected to be permanent.
After almost 15 years since the first gene therapy trial for Duchenne muscular dystrophy (DMD) began, the dream of a DMD gene therapy drug is getting closer to a reality.
Following her time as a Managing Partner at Baxter Ventures and Baxalta Ventures, Vemuri founded Agent Capital, a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.
The vaccine will be dosed at a 30-microgram level with a two-dose regimen. The vaccine is an mRNA product, with the mRNA encoding for the SARS-CoV-2 full length spike glycoprotein (S).
Connolly, who has more than 20 years of experience in immunotherapy, will design the Institute’s overall research strategy and forge new partnerships between the institute and the industry.
PRESS RELEASES